Gavin B. Samuels

Nessuna posizione attualmente

Consumer Services

Health Technology

Profilo

Gavin B.
Samuels is Senior Vice President of Business Development for Quark Pharmaceuticals, Inc. Prior to joining Quark Pharmaceuticals March, 2007 he held several positions at Worldwide Business Development and Worldwide Product Development Groups for Pfizer, Inc. Previously, he was Senior Associate of Healthcare Strategy and Corporate Affairs for Merck Sharpe & Dohme in Australia.
Dr. Samuels received an MS from the University of Witwatersrand, an MBA from the University of New England (Australia) and a degree in Health Economics from Monash University, Australia.

Precedenti posizioni note di Gavin B. Samuels

Società	Posizione	Fine
Quark Pharmaceuticals, Inc. Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA.	Corporate Officer/Principal	23/09/2010
PFIZER, INC.	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Gavin B. Samuels

Formazione di Gavin B. Samuels

University of the Witwatersrand	Doctorate Degree
University of New England (Australia)	Masters Business Admin
Monash University	Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Gavin B. Samuels

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
PFIZER, INC.	Health Technology

Aziende private	1
Quark Pharmaceuticals, Inc. Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA.	Health Technology